Is Origin profitable in 2026?

No. Origin is pre-revenue as of its February 4, 2026 YC launch, with no publicly disclosed customers or pharma contracts. Its launch post explicitly solicited introductions to pharma and biotech partners, indicating no commercial revenue existed at that time.

Could AI replace Origin's technology?

Origin's entire product, an AI model called Axis, already competes directly with Google DeepMind's free AlphaGenome, which was peer-reviewed in Nature on January 28, 2026. If DeepMind iterates further, Origin's self-reported 6.7 percent benchmark edge (as claimed February 4, 2026) could vanish quickly.

Who is Origin's biggest competitor?

Google DeepMind's AlphaGenome is Origin's named benchmark rival: a free, non-commercial, peer-reviewed model (Nature, January 28, 2026) that matches or exceeds prior best models on 24 to 25 of 26 variant-effect benchmarks, per DeepMind's own June 25, 2025 announcement.

Origin is privately held and founder-run, led by CEO Yash Rathod and CTO Malhar Bhide, both with UIUC computer science backgrounds per an October 11, 2025 LinkedIn listing. It is backed by Y Combinator as part of the W26 cohort, with no other investors publicly named.

Does Origin have any pharma partnerships?

No pharma or biotech partnerships were named as of Origin's February 4, 2026 Y Combinator launch. The launch post explicitly asked for introductions to cell and gene therapy companies, indicating none existed at that point.

What does Origin actually build?

Origin builds Axis, an AI model that predicts and generates regulatory DNA sequences, described as 'DNA switches and dials,' to help design safer cell and gene therapies, according to its February 4, 2026 Y Combinator launch post.

YC Winter 2026 · United States

Origin

Origin is a 5-person startup building AI models to predict regulatory DNA for safer gene therapies.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from by early 2027 · Every call on the record Checkpoint: Origin's window to convert its YC launch into a named pharma data partnership

The call

Origin is a small, pre-revenue team claiming a narrow edge over a free DeepMind model, with no named pharma partner and no dataset built yet.

Origin built a computer model that predicts which parts of DNA control genes, and claims it works about 6.7% better than Google DeepMind's AlphaGenome, which anyone can use for free. The real threat is that Google, along with other well-funded labs working on DNA prediction models, can copy or beat Origin's approach much faster than a five-person team can defend it. The only thing that could save Origin is if it builds its own private database of real laboratory experiments that no one else has access to, then gets major pharmaceutical companies to pay for that data and the model together, but that database does not exist yet and no pharma companies have signed up.

Why

AI pressure: Google DeepMind's AlphaGenome. AlphaGenome is free, peer-reviewed, and public; Origin's whole pitch rests on a self-reported 6.7% edge over it. Could AI do the core job? Yes, likely.

Bigger players: Isomorphic Labs (Alphabet). Isomorphic Labs can pair DeepMind's genomic models with pharma money and deals Origin has not landed yet. Could a giant copy it? Yes, easily.

What protects it. None shipped yet; its planned patient-derived cancer single-cell dataset is still a roadmap item, not an asset.

What would change this call

Origin announces a signed pharma or biotech data-partnership within 12 months of its Feb 2026 YC launch. Would show Origin can convert benchmark claims into real commercial traction.
Independent third-party wet-lab validation of Origin's regulatory-DNA predictions appears within 12 months. Would show its 6.7% benchmark edge holds outside self-reported tests.
Isomorphic Labs or Google DeepMind launches a commercial regulatory-DNA therapeutics product within 18 months. Would show the incumbent closing the window before Origin builds a moat.

Key numbers

Claims 6.7% better accuracy than AlphaGenome (2026-02-04)
AlphaGenome leads on 24 of 26 benchmarks (2025-06-25)
$500K pre-seed raised, no follow-on disclosed (2026-06-24)

Named risks

No signed pharma or biotech partnership disclosed despite explicit solicitation at Feb 2026 launch. Severity: high
Core product directly competes with a free, peer-reviewed frontier model from Google DeepMind. Severity: high
Only 4-5 person team with unproven ability to generate proprietary wet-lab data at scale. Severity: medium
Crowded, well-funded peer field including Ginkgo, Recursion, Generate Biomedicines, Deep Genomics. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Google DeepMind (AlphaGenome)	losing to	Free API since 2025-06-25, peer-reviewed Nature 2026-01-28; Origin's 6.7% edge is self-reported, unverified
Ginkgo Bioworks	losing to	Ran GPT-5 autonomous lab campaign by 2026-03-31; Origin remains a 4-person team
Isomorphic Labs (Alphabet)	contesting	Alphabet's pharma commercialization arm could enter genomics markets Origin targets at any time
Generate Biomedicines and Deep Genomics	losing to	Well-funded peers in generative biology vs Origin's small pre-seed, per Feb 2026 reporting

Questions people ask

Is Origin profitable in 2026?: No. Origin is pre-revenue as of its February 4, 2026 YC launch, with no publicly disclosed customers or pharma contracts. Its launch post explicitly solicited introductions to pharma and biotech partners, indicating no commercial revenue existed at that time.
Could AI replace Origin's technology?: Origin's entire product, an AI model called Axis, already competes directly with Google DeepMind's free AlphaGenome, which was peer-reviewed in Nature on January 28, 2026. If DeepMind iterates further, Origin's self-reported 6.7 percent benchmark edge (as claimed February 4, 2026) could vanish quickly.
Who is Origin's biggest competitor?: Google DeepMind's AlphaGenome is Origin's named benchmark rival: a free, non-commercial, peer-reviewed model (Nature, January 28, 2026) that matches or exceeds prior best models on 24 to 25 of 26 variant-effect benchmarks, per DeepMind's own June 25, 2025 announcement.
Who owns Origin?: Origin is privately held and founder-run, led by CEO Yash Rathod and CTO Malhar Bhide, both with UIUC computer science backgrounds per an October 11, 2025 LinkedIn listing. It is backed by Y Combinator as part of the W26 cohort, with no other investors publicly named.
Does Origin have any pharma partnerships?: No pharma or biotech partnerships were named as of Origin's February 4, 2026 Y Combinator launch. The launch post explicitly asked for introductions to cell and gene therapy companies, indicating none existed at that point.
What does Origin actually build?: Origin builds Axis, an AI model that predicts and generates regulatory DNA sequences, described as 'DNA switches and dials,' to help design safer cell and gene therapies, according to its February 4, 2026 Y Combinator launch post.

Timeline

2026-07-26Nature publishes paper on generalizable AI in regulatory genomics, showing a crowded research field
2026-03-31Ginkgo Bioworks and OpenAI report GPT-5 running an autonomous protein-synthesis lab campaign
2026-02-09Yahoo Finance profiles well-funded AI bioengineering peers including Ginkgo, Recursion, Generate
2026-02-05Blog profile describes Origin as a 'lean team of four'
2026-02-04Origin launches publicly via YC, claims Axis beats AlphaGenome by 6.7% (vendor-claimed)
2026-01-28Google DeepMind's AlphaGenome peer-reviewed and published in Nature
2025-10-11LinkedIn lists Origin's founding team, CEO Yash Rathod and CTO Malhar Bhide, UIUC backgrounds
2025-06-25Google DeepMind launches AlphaGenome as a free non-commercial API
2025Origin founded in San Francisco

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

CellType OctaPulse The Token Company